Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone + Buprenorphine for Transition to Vivitrol in OUD
NCT02696434Phase 3Completed
- Sponsor
- Alkermes
- Start
- Apr 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone in opioid use disorder (OUD), sponsored by Alkermes. Primary endpoint: Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection at Day 8. Started Apr 2016; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02696434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696434.